Variable | All treatment groups | |
Sex, N (%) | Male: 373 (45.7) | Female: 443 (54.3) |
Age (years), mean (SD) | 48.0 (12.1) | 49.6 (12.1) |
Race, white, n (%) | 351 (94.1) | 421 (95.0) |
BMI (kg/m2), mean (SD) | 29.5 (5.1) | 29.8 (6.7) |
PsA duration | ||
<2 years | 88 (23.6) | 86 (19.4) |
≥2 years | 285 (76.4) | 357 (80.6) |
SJC (66), mean (SD) | 11.0 (9.0) | 12.2 (9.8) |
TJC (68), mean (SD) | 19.4 (13.8) | 22.0 (14.4)* |
SPARCC, patients included† | ||
n (%) | 290 (77.7) | 337 (76.1) |
Mean (SD) | 4.7 (3.5) | 6.1 (3.9)*** |
LEI, patients included‡ | ||
n (%) | 245 (65.7) | 310 (70.0) |
Mean (SD) | 2.6 (1.6) | 3.0 (1.6)* |
DSS, patients included§ | ||
n (%) | 218 (58.4) | 213 (48.1)* |
Mean (SD) | 8.9 (7.9) | 8.1 (8.3) |
CRP (mg/L), mean (SD) | 14.6 (26.1) | 10.2 (16.2)* |
PASI, patients included¶ | ||
n (%) | 273 (73.2) | 285 (64.3) |
Mean (SD) | 11.4 (9.6) | 8.3 (7.3)*** |
PGA-PsA (VAS in mm), mean (SD) | 61.3 (22.6) (N=372) | 64.2 (22.5) |
PGA-PsO**, n (%) | ||
0 | 11 (2.9) | 20 (4.5) |
1 | 100 (26.8) | 136 (30.7) |
2 | 154 (41.3) | 190 (42.9) |
3 | 92 (24.7) | 80 (18.1) |
4 | 14 (3.8) | 14 (3.2) |
HAQ-DI, mean (SD) | 1.1 (0.6) (N=372) | 1.3 (0.7)*** |
SF-36 PCS, mean (SD) | 35.4 (8.9) (N=370) | 34.1 (8.2)* (N=442) |
SF-36 MCS, mean (SD) | 42.3 (11.8) (N=370) | 38.9 (11.7)*** (N=442) |
FACIT-F, mean (SD) | 30.2 (10.7) (N=372) | 25.5 (10.7)*** |
Patient Global Assessment of Arthritis and Skin (VAS in mm), mean (SD) | 53.6 (19.9) (N=371) | 54.1 (20.3) (N=436) |
Patient Assessment of Arthritis Pain (VAS in mm), mean (SD) | 53.9 (23.7) (N=371) | 56.2 (22.8) |
Presence of depression††, yes, n (%) | 21 (5.6) | 67 (15.1)*** |
*p<0.05, **p<0.001, ***p<0.0001 for females versus males.
†Patients with baseline SPARCC >0.
‡Patients with baseline LEI >0.
§Patients with baseline DSS >0.
¶PASI was assessed in patients with baseline BSA ≥3% and PASI >0.
**PGA-PsO assessed in patients with baseline PGA-PsO >0.
††Ascertained from medical history.
BMI, body mass index; BSA, body surface area; CRP, C-reactive protein; DSS, Dactylitis Severity Score; FACIT-F, Functional Assessment of Chronic Illness Therapy-Fatigue; HAQ-DI, Health Assessment Questionnaire-Disability Index; LEI, Leeds Enthesitis Index; n, number of patients with demographic/clinical characteristic at baseline; N, number of evaluable patients; PASI, Psoriasis Area and Severity Index; PGA-PsA, Physician Global Assessment of PsA; PGA-PsO, Physician Global Assessment of Psoriasis; PsA, psoriatic arthritis; SF-36 PCS, Short Form-36 Physical Component Summary; SJC, swollen joint count; SPARCC, Spondyloarthritis Research Consortium of Canada; TJC, tender joint count; VAS, Visual Analogue Scale.